Lungs & breathing

COPD Inhalers Explained: Rescue vs Maintenance

Save

COPD inhalers fall into two groups: rescue inhalers (short-acting bronchodilators for sudden breathlessness) and maintenance inhalers (long-acting bronchodilators, and inhaled corticosteroids for frequent flare-ups) taken daily to prevent symptoms. There is no single best inhaler — a pulmonologist selects among them based on your symptom burden, exacerbation history, and GOLD disease classification.

Last updated: July 2026History

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why are there so many different COPD inhalers?

COPD causes airflow obstruction through two main mechanisms: bronchoconstriction (tightening of the airway muscles) and inflammation. Different inhaler classes target one or both. The GOLD guidelines recommend a stepwise, personalized approach to inhaler therapy based on how much your symptoms affect daily life and how often you have exacerbations 1.

What is a rescue inhaler (SABA)?

Short-acting beta-2 agonists (SABAs) — the most common example is albuterol (salbutamol) — relax the muscles around the airways within minutes and are used for on-demand relief of breathlessness. They are sometimes called "rescue" inhalers.

SABAs do not treat the underlying disease progression; they relieve acute symptoms 1. Needing your rescue inhaler more than a couple of times a week (outside of exercise) is a signal to review your overall COPD management plan with your pulmonologist.

What are long-acting maintenance inhalers (LABA and LAMA)?

Long-acting beta-2 agonists (LABAs) work by the same mechanism as SABAs but last 12 to 24 hours. Examples include formoterol, salmeterol, and indacaterol. They are used twice daily or once daily depending on the formulation.

Long-acting muscarinic antagonists (LAMAs) work by blocking acetylcholine receptors in the airway, reducing bronchospasm and mucus secretion. They last about 24 hours. Tiotropium (Spiriva) is one of the best-known LAMAs; umeclidinium (found in Anoro Ellipta combined with vilanterol, a LABA) is another.

For most people with COPD who have moderate or more significant symptoms, GOLD guidelines recommend starting with a LAMA, or a LABA/LAMA combination, rather than a LABA alone [1, 2]. LABA/LAMA combinations reduce symptoms and exacerbation rates more than either drug alone in clinical trials.

Comparing Spiriva (tiotropium) and Anoro (umeclidinium/vilanterol): Both are once-daily maintenance inhalers. Spiriva is a LAMA only; Anoro is a LABA/LAMA combination. Your pulmonologist may choose based on your symptom severity, exacerbation history, and cost. These are not interchangeable decisions to make on your own.

What are inhaled corticosteroids (ICS), and who needs them?

Inhaled corticosteroids (ICS) reduce airway inflammation. In COPD, they are not recommended as initial monotherapy and are generally added to a LABA and/or LAMA for specific patients — primarily those with:

  • A history of two or more exacerbations per year despite maintenance bronchodilators
  • Elevated blood eosinophils (a type of white blood cell that predicts ICS response)
  • Features of overlap with asthma

ICS can raise the risk of pneumonia when used in COPD, so their use is more targeted than in asthma 1. Triple therapy (LABA + LAMA + ICS) is reserved for those who qualify based on exacerbation burden 2.

Examples of combination ICS-containing inhalers include Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) and Breztri Aerosphere (budesonide/glycopyrrolate/formoterol).

How do I have a productive conversation about inhalers with my pulmonologist?

Come prepared with:

  • A record of how often you use your rescue inhaler in a typical week
  • A description of which activities you can and cannot do due to breathlessness
  • How many times in the past year you had a flare-up requiring steroids, antibiotics, or a hospital visit
  • Any side effects from current inhalers (throat irritation, dry mouth, racing heart)
  • Your insurance formulary — inhaler costs vary substantially; your pulmonologist can often substitute a covered option with similar clinical effect

Proper inhaler technique matters as much as the medication choice 3. Ask your clinician or pharmacist to watch you use your device — mistakes in technique are extremely common and reduce how much medication reaches the lungs.

Common questions

This is not recommended. Overusing rescue inhalers and skipping maintenance therapy is linked to poorer outcomes and higher exacerbation risk. If cost is a concern, ask your pulmonologist about patient assistance programs or formulary alternatives — there are often lower-cost options with comparable effects.

LAMAs can cause dry mouth, constipation, and urinary difficulty (more relevant in men with prostate issues). LABAs can cause a slightly elevated heart rate. ICS are associated with an increased risk of pneumonia in COPD and can cause oral thrush — rinsing your mouth after each use reduces that risk. Your pulmonologist weighs these against the benefits for your specific situation.

GOLD (Global Initiative for Chronic Obstructive Lung Disease) uses spirometry results and symptom scores to classify COPD severity and guide treatment. Your pulmonologist uses GOLD categories to choose the right intensity of maintenance therapy. Understanding your GOLD category helps you have a more informed conversation about your treatment plan.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Important inhaler safety notes

  • —Never stop or change your maintenance inhaler without talking to your pulmonologist — abrupt changes can trigger exacerbations.
  • —If you are using your rescue inhaler more than twice a week for symptoms (not exercise), contact your pulmonologist — your maintenance therapy may need adjustment.
  • —A rapid or irregular heartbeat after inhaler use, new chest pain, or severe worsening of breathing needs same-day medical attention.

If breathlessness becomes severe and your rescue inhaler is not helping, call 911.

This article explains COPD inhaler classes for educational purposes. Medication selection is a clinical decision made by your pulmonologist based on your spirometry results, symptom scores, exacerbation history, and overall health. Gale does not directly provide pulmonology services but can help coordinate your care.

Did this answer your question?

References

  1. 1.Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. (2023). Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine. doi:10.1164/rccm.202301-0106PP ✓LABA, LAMA, and LABA/LAMA combination recommendations by symptom burden and exacerbation history; ICS-associated pneumonia risk in COPD; SABA as rescue therapy
  2. 2.Global Initiative for Chronic Obstructive Lung Disease (2024). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2024 Report). Global Initiative for Chronic Obstructive Lung Disease. link ✓Stepwise inhaler selection framework including LABA/LAMA combinations and triple therapy criteria; eosinophil-guided ICS use
  3. 3.Chrystyn H, van der Palen J, Sharma R, Barnes N, Delafont B, Mahajan A, Thomas M (2017). Device errors in asthma and COPD: systematic literature review and meta-analysis. npj Primary Care Respiratory Medicine. doi:10.1038/s41533-017-0016-z ✓Inhaler technique errors are extremely common across device types; errors reduce drug delivery to the lungs and clinical efficacy

3 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library